Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

27 Jul 2015

Abstract excerpt

INTRODUCTION: The safety, efficacy and prolonged half-life of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously treated patients with severe haemophilia A was demonstrated in the phase 3 A-LONG and Kids A-LONG studies. Here, we report interim safety and efficacy data from the rFVIIIFc extension study, ASPIRE (ClinicalTrials.gov #NCT01454739). METHODS: Eligible subjects could enrol in ASPIRE upon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood transfusion and management
Share to Hemophilia Treatment and Research
Share to Protein purification and stability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26218032
DOI: 10.1111/hae.12766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia APMID 26218032Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

The long and short of it: using the new factor products.Semantic proximity Read ↗

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Semantic proximity Read ↗

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia BSemantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialSemantic proximity Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIISemantic proximity Read ↗

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialSemantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.